Rosacea Patent Study

Title: United States Patent 7,179,78,B2
Study: Compositions and Methods For Treatment of Rosacea
Background
Rosacea is a chronic inflammatory skin disorder characterized by four distinct clinical stages predominantly affecting the central aspect of the face. The first clinical evidence of rosacea is frequent and intense vasodilation or flushing. Most patients progress to a vascular stage characterized by an erythema that can persist for hours or days after a triggering event. Many patients remain stabilized at this stage while some progress to an inflammatory stage characterized by persistent erythema.
Treatments for rosacea commonly involve topical or oral antibiotics such as metronidazole and compounds such as sulfacetamide, sulfur, and azelaic acid. However, these and the other treatments for rosacea are accompanied by various side effects, are costly, and/or involve long complicated treatment protocols. Accordingly, there remains a need in the art for more effective and otherwise improved methods for treating dermatological conditions related to rosacea by, for example, topically applying compositions, having a desired degree of effectivity, to areas of the skin of a patient in need hereof. The present invention fulfills this need and provides further related advantages.
Methods
The utility of the composition was demonstrated in a 12-week human patient study. More specifically, the cream, containing glycyl-L-histidyl-L-lysine:copper(II), was tested for its effect on rosacea. The cream was applied as a thin film to the lesions twice each day, once in the morning and once at night; for the 5 patients showing an effect, the improvement was 70%. The overall reduction of lesions for all 8 patients treated was 26%.
At the beginning of the study, and at weeks 6 and 12, the number of inflammatory lesions (papules and pustules) was determined.
Results
The Rosacea Global Score, was used to evaluate improvement.
1= Almost clear: absence of inflammatory lesions, or 25 presence of a few small involuted lesions, trace of erythema, presence or absence of telangiectasias.
2= Mild: few small inflammatory lesions, mild erythema
3= Moderate: Moderate number of inflammatory lesions, moderate to severe erythema, presence of telangiectasias.
4= Severe: large number of inflammatory lesions, moderate to sever erythema, presence of telangiectasias.Â
In a similar manner, 4 of the 8 patients showed a 50% decrease in the Rosacea Global Score, going from the "mild" to the "almost clear" category within the 12-week study period, thereby, indicating a response to the peptide copper treatment during that period.
Thus, the above examples demonstrate the effectiveness of the method the present invention in alleviating the signs and symptoms of rosacea.



